COURT-RULING ·Filed Jul 2, 2026

TFX

TELEFLEX INC
BULLISH
Impact 6/10
Horizonimmediate Processed3mo ago CourtView Ruling on CourtListener
Court ruling (appellate)
Actionable Insight ▲ Bullish

The complete removal of patent infringement liability for the McGrath Series 5 laryngoscope eliminates a key overhang. Traders should monitor for any petition for certiorari, though the nonprecedential nature and strong intrinsic record make Supreme Court review unlikely.

DirectionBullish
Confidencehigh
Horizonimmediate
Latest settled — T+60d
TFX ▼ -10.37% at T+60d
LONG call ✗ call lost -10.37% · α vs SPY -13.38% · entry $133.99 → $120.09
Next anchor: T+1d due 3mo ago
Entry anchored
Jul 1, 03:59 PM ET
via exchange tick
T+1d
—
call — · α —
—
due 3mo ago
T+5d
+0.04%
call +0.04% · α -0.89%
$134.04
settled 3mo ago
T+20d
-1.26%
call -1.26% · α -0.85%
$132.30
settled 2mo ago
T+60d
-10.37%
call -10.37% · α -13.38%
$120.09
settled 7d ago

Price Chart

Loading chart...

Executive Summary

The Federal Circuit affirmed summary judgment of noninfringement in favor of Teleflex Medical Inc., ending a patent infringement suit over video laryngoscope technology. The court upheld the district court's claim construction of 'mounted on' as 'fastened to the exterior of' and found no genuine issues of material fact regarding literal or equivalent infringement. This removes litigation uncertainty and potential damages exposure for Teleflex's McGrath Series 5 products.

Court Ruling Details

Ruling Date
Jul 2, 2026
Court
Court of Appeals for the Federal Circuit
Court Level
Appellate
Judge
Stoll
Case Type
patent
Ruling Type
final judgment
Outcome
WIN — ruling favors this company
Will It Be Appealed?
Unlikely
Precedent Risk
LOW

Key Facts

  • Federal Circuit affirmed summary judgment of noninfringement for Teleflex on all asserted claims of U.S. Patent No. 5,827,178
  • Court adopted claim construction of 'mounted on' as 'fastened to the exterior of', which the accused McGrath Series 5 products did not meet
  • No damages awarded and no injunction issued; case is concluded
  • Ruling is nonprecedential, limiting broader precedent risk

Financial Impact

No damages awarded; litigation risk eliminated for McGrath Series 5 product line

litigation expenseproduct liability risk

Risk Factors

  • Low risk of certiorari petition to the Supreme Court
  • Nonprecedential ruling does not bind other courts on similar claim terms

Market Snapshot

Exchange
NYSE
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
35% bullish (17 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 court opinion from CourtListener.

DocumentAccession Number
COURT-RULING Data (Synthetic)court-3lass4y1-TFX
9 reports for TFX
Performance horizon
Filters
Rows
Reports for TFX — sortable, filterable
TypeNow
Aug 6, 2026
8w ago
8-K
MIXED ★ 6/10
$138.89 $139.96▲ +0.77%▲ +0.17%$124.58 (−10.30%)
Jul 2, 2026
13w ago
Court Ruling
BULLISH ★ 6/10
$133.99 $132.30▼ −1.26%▼ −0.85%$124.58 (−7.02%)
Jun 22, 2026
14w ago
Institutional Cluster
MIXED ★ 4/10
$121.67 $134.61▲ +10.64%▲ +10.78%$124.58 (+2.39%)
Jun 15, 2026
15w ago
8-K
NEUTRAL ★ 4/10
$127.87 $130.16▲ +1.79%▲ +1.59%$124.58 (−2.57%)
Jun 9, 2026
16w ago
8-K
NEUTRAL ★ 2/10
$132.15 $134.04▲ +1.43%▼ −2.19%$124.58 (−5.73%)
Jun 1, 2026
17w ago
8-K
NEUTRAL ★ 4/10
$127.31 $127.49▲ +0.14%▲ +2.45%$124.58 (−2.15%)
May 27, 2026
18w ago
8-K
NEUTRAL ★ 4/10
$128.90 $127.79▼ −0.86%▲ +1.83%$124.58 (−3.35%)
May 7, 2026
21w ago
8-K
MIXED ★ 6/10
$131.59 $128.56▼ −2.31%▼ −5.44%$124.58 (−5.33%)
Feb 26, 2026
31w ago
8-K
MIXED ★ 7/10
$118.39 $110.38▼ −6.77%▼ −0.36%$124.58 (+5.22%)
Showing 9 of 9

US Market Status

Market Open — Closes in 20m

Subscribe to SecBot

Get Real-Time Court Ruling Intelligence

Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access